These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 21492926)

  • 1. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
    Samandari T; Agizew TB; Nyirenda S; Tedla Z; Sibanda T; Shang N; Mosimaneotsile B; Motsamai OI; Bozeman L; Davis MK; Talbot EA; Moeti TL; Moffat HJ; Kilmarx PH; Castro KG; Wells CD
    Lancet; 2011 May; 377(9777):1588-98. PubMed ID: 21492926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuberculosis incidence after 36 months' isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis.
    Samandari T; Agizew TB; Nyirenda S; Tedla Z; Sibanda T; Mosimaneotsile B; Motsamai OI; Shang N; Rose CE; Shepherd J
    AIDS; 2015 Jan; 29(3):351-9. PubMed ID: 25686683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isoniazid-associated hepatitis in adults infected with HIV receiving 36 months of isoniazid prophylaxis in Botswana.
    Tedla Z; Nguyen ML; Sibanda T; Nyirenda S; Agizew TB; Girde S; Rose CE; Samandari T
    Chest; 2015 May; 147(5):1376-1384. PubMed ID: 25340318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
    Tedla Z; Nyirenda S; Peeler C; Agizew T; Sibanda T; Motsamai O; Vernon A; Wells CD; Samandari T
    Am J Respir Crit Care Med; 2010 Jul; 182(2):278-85. PubMed ID: 20378730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.
    Ndiaye BP; Thienemann F; Ota M; Landry BS; Camara M; Dièye S; Dieye TN; Esmail H; Goliath R; Huygen K; January V; Ndiaye I; Oni T; Raine M; Romano M; Satti I; Sutton S; Thiam A; Wilkinson KA; Mboup S; Wilkinson RJ; McShane H;
    Lancet Respir Med; 2015 Mar; 3(3):190-200. PubMed ID: 25726088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial.
    Rangaka MX; Wilkinson RJ; Boulle A; Glynn JR; Fielding K; van Cutsem G; Wilkinson KA; Goliath R; Mathee S; Goemaere E; Maartens G
    Lancet; 2014 Aug; 384(9944):682-90. PubMed ID: 24835842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease.
    Mohammed A; Myer L; Ehrlich R; Wood R; Cilliers F; Maartens G
    Int J Tuberc Lung Dis; 2007 Oct; 11(10):1114-20. PubMed ID: 17945069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.
    Halsey NA; Coberly JS; Desormeaux J; Losikoff P; Atkinson J; Moulton LH; Contave M; Johnson M; Davis H; Geiter L; Johnson E; Huebner R; Boulos R; Chaisson RE
    Lancet; 1998 Mar; 351(9105):786-92. PubMed ID: 9519950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial.
    Hosseinipour MC; Bisson GP; Miyahara S; Sun X; Moses A; Riviere C; Kirui FK; Badal-Faesen S; Lagat D; Nyirenda M; Naidoo K; Hakim J; Mugyenyi P; Henostroza G; Leger PD; Lama JR; Mohapi L; Alave J; Mave V; Veloso VG; Pillay S; Kumarasamy N; Bao J; Hogg E; Jones L; Zolopa A; Kumwenda J; Gupta A;
    Lancet; 2016 Mar; 387(10024):1198-209. PubMed ID: 27025337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data.
    Ross JM; Badje A; Rangaka MX; Walker AS; Shapiro AE; Thomas KK; Anglaret X; Eholie S; Gabillard D; Boulle A; Maartens G; Wilkinson RJ; Ford N; Golub JE; Williams BG; Barnabas RV
    Lancet HIV; 2021 Jan; 8(1):e8-e15. PubMed ID: 33387480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tuberculosis treatment outcomes in HIV-infected adults exposed to isoniazid preventive therapy in Botswana.
    Sibanda T; Tedla Z; Nyirenda S; Agizew T; Marape M; Miranda AG; Reuter H; Johnson JL; Samandari T
    Int J Tuberc Lung Dis; 2013 Feb; 17(2):178-85. PubMed ID: 23317952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
    ; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
    N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania.
    Kabali C; von Reyn CF; Brooks DR; Waddell R; Mtei L; Bakari M; Matee M; Pallangyo K; Arbeit RD; Horsburgh CR
    Int J Tuberc Lung Dis; 2011 Nov; 15(11):1515-21, i. PubMed ID: 22008766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial.
    Hawken MP; Meme HK; Elliott LC; Chakaya JM; Morris JS; Githui WA; Juma ES; Odhiambo JA; Thiong'o LN; Kimari JN; Ngugi EN; Bwayo JJ; Gilks CF; Plummer FA; Porter JD; Nunn PP; McAdam KP
    AIDS; 1997 Jun; 11(7):875-82. PubMed ID: 9189212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
    Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
    JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
    Durovni B; Saraceni V; Moulton LH; Pacheco AG; Cavalcante SC; King BS; Cohn S; Efron A; Chaisson RE; Golub JE
    Lancet Infect Dis; 2013 Oct; 13(10):852-8. PubMed ID: 23954450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Financial incentives for reduced alcohol use and increased isoniazid adherence during tuberculosis preventive therapy among people with HIV in Uganda: an open-label, factorial randomised controlled trial.
    Chamie G; Hahn JA; Kekibiina A; Emenyonu NI; Beesiga B; Marson K; Fatch R; Lodi S; Adong J; Thirumurthy H; McDonell MG; Gandhi M; Bryant K; Havlir DV; Kamya MR; Muyindike WR
    Lancet Glob Health; 2023 Dec; 11(12):e1899-e1910. PubMed ID: 37973340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial.
    Fitzgerald DW; Desvarieux M; Severe P; Joseph P; Johnson WD; Pape JW
    Lancet; 2000 Oct; 356(9240):1470-4. PubMed ID: 11081529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial.
    Gupta A; Singh P; Aaron L; Montepiedra G; Chipato T; Stranix-Chibanda L; Chanaiwa V; Vhembo T; Mutambanengwe M; Masheto G; Raesi M; Bradford S; Golner A; Costello D; Kulkarni V; Shayo A; Kabugho E; Jean-Phillippe P; Chakhtoura N; Sterling TR; Theron G; Weinberg A;
    Lancet Child Adolesc Health; 2023 Oct; 7(10):708-717. PubMed ID: 37634517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Annual Tuberculosis Preventive Therapy for Persons With HIV Infection : A Randomized Trial.
    Churchyard G; Cárdenas V; Chihota V; Mngadi K; Sebe M; Brumskine W; Martinson N; Yimer G; Wang SH; Garcia-Basteiro AL; Nguenha D; Masilela L; Waggie Z; van den Hof S; Charalambous S; Cobelens F; Chaisson RE; Grant AD; Fielding KL;
    Ann Intern Med; 2021 Oct; 174(10):1367-1376. PubMed ID: 34424730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.